Abstract
At present cancer treatment is still a confusing problem. Great progress has been made in anti-tumor agents since a series of small molecules are approved by FDA as anti-tumor drugs. Nitroimidazoles is a kind of radiosensitizer with multiple bioactivities used in cancer treatment since 1950s. In this review, we focus on the development of nitroimidazoles as radiosensitizer, bio-reductive prodrug and other types of anti-tumor agents for cancer therapy, and the mechanism of acting as anti-tumor agents. Finally, we also discuss the prospect and developmental trend of nitroimidazoles as anti-tumor agents.
Keywords: Anti-tumor, 2-Nitroimidazole, Hypoxic cell radiosensitizer, Bio-reductive prodrug, Abl tyrosine kinase inhibitor, nitroimidazoles, synergistic effect, normoxia, chemotherapy
Anti-Cancer Agents in Medicinal Chemistry
Title: Nitroimidazoles as Anti-Tumor Agents
Volume: 11 Issue: 7
Author(s): Kai Liu and Hai-Liang Zhu
Affiliation:
Keywords: Anti-tumor, 2-Nitroimidazole, Hypoxic cell radiosensitizer, Bio-reductive prodrug, Abl tyrosine kinase inhibitor, nitroimidazoles, synergistic effect, normoxia, chemotherapy
Abstract: At present cancer treatment is still a confusing problem. Great progress has been made in anti-tumor agents since a series of small molecules are approved by FDA as anti-tumor drugs. Nitroimidazoles is a kind of radiosensitizer with multiple bioactivities used in cancer treatment since 1950s. In this review, we focus on the development of nitroimidazoles as radiosensitizer, bio-reductive prodrug and other types of anti-tumor agents for cancer therapy, and the mechanism of acting as anti-tumor agents. Finally, we also discuss the prospect and developmental trend of nitroimidazoles as anti-tumor agents.
Export Options
About this article
Cite this article as:
Liu Kai and Zhu Hai-Liang, Nitroimidazoles as Anti-Tumor Agents, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (7) . https://dx.doi.org/10.2174/187152011796817664
DOI https://dx.doi.org/10.2174/187152011796817664 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alternative and New Radiopharmaceutical Agents for Lung Cancer
Current Radiopharmaceuticals Overview of Mechanisms of Cancer Stem Cell Drug Resistance
Current Signal Transduction Therapy Polyethylenimine-based Formulations for Delivery of Oligonucleotides
Current Medicinal Chemistry Combining Anti-Epidermal Growth Factor Receptor (EGFR) and Anti-Angiogenic Strategies in Advanced NSCLC: We Should have Known Better...
Current Pharmaceutical Design An overview of ABC and SLC Drug Transporter Gene Regulation
Current Drug Metabolism Recent Advances in Targeted Anti-Vasculature Therapy: The Neuroblastoma Model
Current Drug Targets Bench to Bedside Targeting of FLT3 in Acute Leukemia
Current Drug Targets Editorial (Thematic Issue : Frontier View on Drug Discoveries for Different Diseases - Part I )
Current Drug Metabolism Bio-analytical Identification of Key Genes that Could Contribute to the Progression and Metastasis of Osteosarcoma
Current Bioinformatics Liquid Biopsy as Surrogate to Tissue in Lung Cancer for Molecular Profiling: A Meta-analysis
Current Respiratory Medicine Reviews PARP Inhibitors: An Interesting Pathway also for Non-Small Cell Lung Cancer?
Current Pharmaceutical Design HIV and Respiratory Disease: A Contemporary Perspective
Current Respiratory Medicine Reviews RNA Silencing: Recent Developments on miRNAs
Recent Patents on DNA & Gene Sequences Immune Checkpoints Aberrations and Malignant Mesothelioma: Assessment of Prognostic Value and Evaluation of Therapeutic Potentials
Anti-Cancer Agents in Medicinal Chemistry Nuclear Export Mediated Regulation of MicroRNAs: Potential Target for Drug Intervention
Current Drug Targets Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment
Current Cancer Therapy Reviews The PARAMOUNT Trial: A Phase III Randomized Study of Maintenance Pemetrexed Versus Placebo Immediately Following Induction First-line Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer
Reviews on Recent Clinical Trials Fc Engineering to Improve the Function of Therapeutic Antibodies
Current Pharmaceutical Biotechnology Antitumor Pharmacology - Quo Vadis ?
Current Medicinal Chemistry - Anti-Cancer Agents Paraneoplastic Pemphigus: Autoimmune-Cancer Nexus in the Skin
Anti-Cancer Agents in Medicinal Chemistry